Creso Pharma’s vital competitive advantages key to the future
4 minute read
In a development that highlights the substantial benefits of a proposed merger between Creso Pharma Limited (ASX:CPH, FRA:1X8) and Red Light Holland, the former has secured its first purchase order from Red Light Holland’s wholly-owned distribution company SR Wholesale B.V.
This relates to Creso Pharma’s leading range of Swiss manufactured hemp CBD products, marking the first purchase order between Red Light Holland and Creso Pharma, and an important step ahead of the proposed creation of The HighBrid Lab.
In further news that reinforces the long-term shareholder value that can be generated by the merged entities, the parties are also aggressively pursuing product development initiatives across the psychedelics sector.
Should the proposed merger with Red Light Holland be approved, The Hybrid Lab will explore the potential of combining functional mushrooms and other compounds with Creso Pharma’s existing product suite.
The purchase order for Creso Pharma’s cannaQIX® hemp CBD lozenges and cannaQIX® hemp instant tea announced today is valued at CHF152,220 (A$218,803 ).
The products will be introduced under the established iMicrodose and/or other Red Light Holland brands.
Pursuant to the purchase order, Red Light Holland and SR Wholesale will market and distribute the products across the Netherlands underlining the vertically integrated efficiencies and supply chain management benefits that the combined entity could potentially deliver.
Commenting on this development, Creso Pharma non-executive chairman Adam Blumenthal said, “The maiden purchase order between Red Light Holland and Creso Pharma is an important milestone for both parties, and demonstrates the synergies and strategic opportunities driving the merger of the two companies.
"Red Light Holland has a number of established brands in the Netherlands, which are well known and trusted by consumers and to be able to white label our leading Swiss manufactured product suite through these has a number of competitive advantages to drive increased sales.
"We look forward to leveraging SR Wholesale’s distribution network to create a strong foundation for future growth.”
SR Wholesale distributes to more than 400 companies
SR Wholesale has a very strong market presence in the Netherlands, as well as an established distribution network of over 400 companies that sell CBD and other products across Europe.
This includes a number of sub-distributors, which provide access to over 1,000 shops across the Netherlands, Spain, Germany, UK, France and Portugal.
It is worth noting that similar to the US, regulatory conditions are being eased across Europe, a factor that is likely to continue, providing further opportunities for revenue growth.
On this note, market research recently conducted in the US has found that nearly a third of American consumers surveyed want cannabis to be sold in their local grocery stores.
Creso Pharma’s Swiss-manufactured products use innovative buccal formulations that enhance the bioavailability of the active ingredients.
Each product has been developed following considerable capital expenditure and R&D undertaken by Creso Pharma’s experienced management team in Switzerland.
Notably, Creso Pharma’s hemp tea products are based on full-spectrum hemp plants and utilise innovative technology to optimise the hemp CBD content allowing for a superior product taste.
Hemp tea considered food in a hemp extract regulated market
The company uses native tea instead of extracts, allowing Creso Pharma to sell the product in countries where hemp tea is considered food and hemp extract is regulated, enhancing Creso Pharma’s, and now Red Light Holland’s, ability to expand market reach.
This purchase order is an important first step in the potential merger of Red Light Holland and Creso Pharma to create The HighBrid Lab.
The introduction of these products will provide existing SR Wholesale customers with a greater understanding of Creso Pharma’s leading products and formulations.
Discussing the potential value-adding benefits of the companies’ multi-faceted product offering, Blumenthal said, “We continue to work very closely with Red Light Holland’s management team to explore potential product development initiatives that may involve the combination of functional mushrooms and other compounds into our existing CBD product lines.
"We intend to initially focus on both lozenge and tea delivery methods and leverage the existing knowledge to our Swiss-based management, as well as Red Light Holland’s extensive experience to progress the introduction of these new products as quickly as possible.
"We anticipate that orders from SR Wholesale will grow as customers and consumers realise the significant benefits of our CBD products.”
Not only is Creso Pharma geared to position itself as an entity with multiple revenue streams and a highly diversified geographical market presence through the proposed establishment of The Hybrid Lab, it is also providing investors with an alternative form of investment in the sector where it is much easier to create competitive advantages through combined product offerings and an integrated supply chain management system where distributors are less likely to encounter product supply disruptions.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.